KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) EPS (Basic) (2020 - 2025)

Recursion Pharmaceuticals' EPS (Basic) history spans 6 years, with the latest figure at -$0.17 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 70.18% year-over-year to -$0.17; the TTM value through Dec 2025 reached -$1.44, up 15.29%, while the annual FY2025 figure was -$1.44, 14.79% up from the prior year.
  • EPS (Basic) reached -$0.17 in Q4 2025 per RXRX's latest filing, up from -$0.36 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.17 in Q4 2025 to a low of -$1.33 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.42, with a median of -$0.38 recorded in 2022.
  • Peak YoY movement for EPS (Basic): crashed 56.47% in 2021, then surged 75.19% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at -$0.39 in 2021, then rose by 23.08% to -$0.3 in 2022, then crashed by 40.0% to -$0.42 in 2023, then plummeted by 35.71% to -$0.57 in 2024, then soared by 70.18% to -$0.17 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's EPS (Basic) are -$0.17 (Q4 2025), -$0.36 (Q3 2025), and -$0.41 (Q2 2025).